🇺🇸 FDA
Patent

US 11584735

Solid forms of a plasma kallikrein inhibitor and salts thereof

granted A61KA61K31/444A61P

Quick answer

US patent 11584735 (Solid forms of a plasma kallikrein inhibitor and salts thereof) held by KalVista Pharmaceuticals Limited expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
KalVista Pharmaceuticals Limited
Grant date
Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/444, A61P, A61P3/10